What it is
CJC-1295 is a synthetic GHRH analog. The no-DAC label indicates a formulation or variant distinction that must be confirmed analytically.
Mechanism and research questions
- GHRH analogs are studied for stimulation of growth-hormone signaling through the GHRH receptor.
- The pharmacokinetics of a no-DAC preparation should not be assumed from DAC-linked studies.
Human evidence
Human evidence for CJC-1295 does not automatically establish the no-DAC variant or a commercial preparation.
Preclinical / mechanistic evidence
Mechanistic rationale is based on GHRH-analog pharmacology, not a validated protocol for this SKU.
Evidence summary
The exact catalog variant needs sequence, purity, and pharmacokinetic documentation before stronger research claims are used.
Limits and interpretation
- Do not transfer DAC-linked exposure data to no-DAC material.
- Identity and stability should be batch-specific.
- No dosing or endocrine manipulation advice is provided.
Regulatory and identity note
Research-use peptide label; not presented as approved therapy.